359 related articles for article (PubMed ID: 23865368)
21. Colorectal cancer screening for average-risk North Americans: an economic evaluation.
Heitman SJ; Hilsden RJ; Au F; Dowden S; Manns BJ
PLoS Med; 2010 Nov; 7(11):e1000370. PubMed ID: 21124887
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of screening for colorectal cancer in the general population.
Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
[TBL] [Abstract][Full Text] [Related]
23. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
24. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I
Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616
[TBL] [Abstract][Full Text] [Related]
25. Cost Effectiveness of Colorectal Cancer Screening Interventions with Their Effects on Health Disparity Being Considered.
Lee KS; Park EC
Cancer Res Treat; 2016 Jul; 48(3):1010-9. PubMed ID: 26727714
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer.
Pil L; Fobelets M; Putman K; Trybou J; Annemans L
Eur J Intern Med; 2016 Jul; 32():72-8. PubMed ID: 27157827
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness and cost-effectiveness analysis of a urine metabolomics test vs. alternative colorectal cancer screening strategies.
Barichello S; Deng L; Ismond KP; Loomes DE; Kirwin EM; Wang H; Chang D; Svenson LW; Thanh NX
Int J Colorectal Dis; 2019 Nov; 34(11):1953-1962. PubMed ID: 31673772
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years.
Ladabaum U; Mannalithara A; Meester RGS; Gupta S; Schoen RE
Gastroenterology; 2019 Jul; 157(1):137-148. PubMed ID: 30930021
[TBL] [Abstract][Full Text] [Related]
29. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of colorectal cancer screening methods in Iran.
Allameh Z; Davari M; Emami MH
Arch Iran Med; 2011 Mar; 14(2):110-4. PubMed ID: 21361717
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.
Sharp L; Tilson L; Whyte S; O'Ceilleachair A; Walsh C; Usher C; Tappenden P; Chilcott J; Staines A; Barry M; Comber H
Br J Cancer; 2012 Feb; 106(5):805-16. PubMed ID: 22343624
[TBL] [Abstract][Full Text] [Related]
32. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness and projected national impact of colorectal cancer screening in France.
Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.
Wu GH; Wang YM; Yen AM; Wong JM; Lai HC; Warwick J; Chen TH
BMC Cancer; 2006 May; 6():136. PubMed ID: 16723013
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
[TBL] [Abstract][Full Text] [Related]
36. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
O'Leary BA; Olynyk JK; Neville AM; Platell CF
J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
[TBL] [Abstract][Full Text] [Related]
38. Willingness to Pay for Colorectal Cancer Screening and Effect of Copayment in Southern Thailand.
Saengow U; Birch S; Geater A; Chongsuwiwatvong V
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1727-1734. PubMed ID: 29938473
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer.
Aronsson M; Carlsson P; Levin LÅ; Hager J; Hultcrantz R
Br J Surg; 2017 Jul; 104(8):1078-1086. PubMed ID: 28561259
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China.
Ren Y; Zhao M; Zhou D; Xing Q; Gong F; Tang W
Front Public Health; 2022; 10():952378. PubMed ID: 36033786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
